Samuel Givertz is a litigation associate whose practice spans complex commercial disputes, high-stakes arbitrations, and government and internal investigations. He represents leading companies and executives in matters involving intellectual property, trade secrets, healthcare contracting, employment and securities issues, and alleged False Claims Act violations. His experience includes major federal litigation over the use of copyrighted works in generative AI systems, multi-million-dollar product liability and contract disputes, and arbitration and regulatory proceedings with substantial public and financial implications.
Before joining Hueston Hennigan, Mr. Givertz practiced at Cravath, Swaine & Moore LLP and served as a law clerk to the Hon. Anthony J. Scirica of the U.S. Court of Appeals for the Third Circuit and the Hon. John P. Cronan of the U.S. District Court for the Southern District of New York.
During school, Mr. Givertz served as comments editor on the University of Pennsylvania Law Review and received multiple academic awards.
Experience
Representing the major record labels, including UMG Recordings, Warner Music Group and Sony Music Entertainment, in high-profile, high-stakes copyright litigation against two leading generative AI music companies, Suno and Udio. The lawsuits are the first time the record labels have sued AI companies over sound recording copyrights. (See “AI Cos. Hit With Copyright Claims From Music Labels,” Law360; “Major record labels sue AI company behind ‘BBL Drizzy,’” The Verge; “Music Labels Take On AI Startups With New Lawsuits,” The Wall Street Journal; “AI’s Most Ambitious Music Generators Accused of ‘Massive’ Infringement In New Lawsuit,” Rolling Stone).
Representing Joe E. Kiani, founder and former CEO of global medical technology company Masimo Corporation, in multiple business, employment, and securities actions with hundreds of millions of dollars at stake.
Representing two California agencies against claims of trade secret misappropriation and breach of contract arising out of a project to develop and implement California’s online health insurance exchange.
Representing AbbVie, a defendant in the multibillion-dollar Allergan textured breast implant litigation, which involves approximately 1,700 individual lawsuits and a nationwide class action in four venues, including multidistrict litigation in the District of New Jersey. The plaintiffs contend AbbVie’s BIOCELL® textured breast implants cause a rare type of cancer, and they argue AbbVie is liable under manufacturing defect, failure to warn, and misrepresentation theories.